Skip to main content

Table 1 Patient characteristics and clinical status at baseline

From: The effect of financial incentives on patients’ motivation for treatment: results of “Money for Medication,” a randomised controlled trial

Variable

Total (n = 169)

Intervention group (n = 84)

Control group (n = 85)

Age mean (SD), years

40.7 (9.8)

40.6 (9.4)

40.7 (10.2)

Gender, N (%)

 - Male

127 (75.1)

61 (72.6)

66 (77.6)

Patients > 50% medication adherence, N (%)

135 (79.9)

68 (80.0)

67 (79.8)

Place of treatment, N (%)

 - The Hague

46 (27.2)

18 (21.4)

18 (21.2)

 - Rotterdam

123 (72.8)

66 (78.6)

67 (78.8)

Substance use disorder, N (%)

94 (55.6)

48 (57.1)

46 (54.1)

Antipsychotic Medication side effects, mean (SD)

4,8 (4,0)

5,3 (4,0)

4,3 (3,9)

Illness insight; median (interquartile range) (range 1–7)

3 (1–4)

3 (1–4)

2 (1–4)

Health of the Nation Outcome Scales (HoNOS), N (%)

 - No motivational problems

136 (80.4)

66 (78.6)

70 (82.3)

 - Severe motivational problems

28 (16.6)

17 (20.2)

11 (12.9)

 - Item missing

5 (3.0)

1 (1.2)

4 (4.8)

Treatment Entry Questionnaire, (TEQ) N (%)

85 (50.3)

42 (50.0)

43 (50.6)

 - External motivation; mean (SD), (range 12–84)

18.4 (7.8)

17.6 (8.1)

19.0 (7.6)

 - Introjected motivation; mean (SD), (range 6–42)

18.7 (10.6)

19.3 (9.4)

18.2 (9.4)

 - Identified motivation; mean (SD), (range 9–63)

28.5 (10.0)

28.6 (10.9)

28.5 (9.2)